Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High After Strong Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares hit a new 52-week high during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $84.49 and last traded at $83.8980, with a volume of 28401 shares traded. The stock had previously closed at $83.59.

The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 232.11% and a net margin of 24.86%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Analysts Set New Price Targets

Several brokerages have weighed in on HALO. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 31st. TD Cowen raised their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday. HC Wainwright lifted their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday. Citizens Jmp boosted their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $91.20.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 72,477 shares of company stock worth $5,102,643. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HALO. Empowered Funds LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth about $195,000. Hsbc Holdings PLC grew its position in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. increased its stake in shares of Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 650 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 20.2%

The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The company has a market capitalization of $12.23 billion, a P/E ratio of 30.78, a P/E/G ratio of 0.36 and a beta of 0.85. The stock has a 50-day moving average price of $76.48 and a 200-day moving average price of $71.47.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.